Twist Bioscience Stock Plunges 18% After Earnings — Its Market Value Falls By $1.4 Billion
Quarterly revenue rose 28% and losses narrowed, while management outlined another year of growth and $75 million in capital spending.
Twist Bioscience, which makes synthetic DNA and research tools, plunged 17.7% in Thursday trading after its earnings report, erasing $1.4 billion in market value. The company posted higher quarterly revenue and a narrower loss in its fourth-quarter and full-year 2026 results, released in Thursday's SEC filing.
A Selloff After Sales Growth
TWST shares fell to $100.92 in Thursday trading, as of 9:46 AM ET, leaving the company with a market value of about $6.7 billion. The stock was on pace for its third drop of 10% or more this month.
Fourth-quarter revenue rose 28% to $126.6 million. The net loss narrowed to $20.6 million, compared with $27.1 million a year earlier.
Management expressed confidence in AI growth on the earnings call. Analysts questioned the slower growth in the company's forecast.
A 287% Gain Before Thursday
Twist's retreat was already underway before the results. Shares had fallen 23% over the previous month through Wednesday's close, but were still up 287% year to date, compared with an 11% gain for the S&P 500.
The company's earlier quarterly report put revenue at $118.4 million, up 23.2% from a year earlier, with a $35.1 million net loss.
Twist uses a silicon-chip manufacturing platform to produce custom genes and other DNA products. Its products help researchers engineer biology, prepare genetic-sequencing samples and develop antibody-based drugs.
Customers include biotechnology and pharmaceutical companies, diagnostic businesses, hospitals and academic researchers, along with chemical and agricultural businesses. Twist earns money from product sales and antibody discovery services, including licensing fees and some milestone payments.
In fiscal 2025, it served more than 3,800 customers globally and generated $376.6 million in revenue. It had 979 employees as of September 30, 2025.
Growth Plans Carry $75 Million Spending
A $75 million capital-spending plan accompanies management's expectation of approximately $550 million to $560 million in annual revenue.
A $130 million to $132 million revenue forecast from Twist covers the quarter ending in December.
Twist enters that quarter with growing sales, a narrower fourth-quarter loss and a substantial capital-spending plan.
Sources
- Twist Bioscience Stock Crashes Despite Quarterly Beat, Solid Guidance | Investor's Business Daily — investors.com
- Twist Bioscience: Fiscal Q4 Earnings Snapshot | wfaa.com — Associated Press
- Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026 – Company Announcement - FT.com — Financial Times
- Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) – Company Announcement - FT.com — Financial Times
- Twist Bioscience Stock Has The Bull Case Changed After MRD Panel Launch? — Yahoo Finance
- The company's filing (Twist Bioscience) — SEC filing
- Twist Bioscience — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR